(Q43596241)

25 November 2017

title

Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours (English)

1 reference

25 November 2017

T Aparicio

1

1 reference

25 November 2017

M Ducreux

2

1 reference

25 November 2017

E Baudin

3

1 reference

25 November 2017

J C Sabourin

4

1 reference

25 November 2017

T De Baere

5

1 reference

25 November 2017

E Mitry

6

1 reference

25 November 2017

M Schlumberger

7

1 reference

25 November 2017

P Rougier

8

1 reference

25 November 2017

publication date

1 May 2001

1 reference

European Journal of Cancer

25 November 2017

published in

1 reference

25 November 2017

volume

37

1 reference

25 November 2017

issue

8

1 reference

25 November 2017

page(s)

1014-1019

1 reference

An analysis of 8305 cases of carcinoid tumors

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900073-9

7 January 2021

Current approach to the management of tumoral process in patients with gastrinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900073-9

7 January 2021

Carcinoid tumors: a 37-year experience

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900073-9

7 January 2021

Karnofsky memorial lecture. An odyssey in the land of small tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900073-9

7 January 2021

Streptozocin–Doxorubicin, Streptozocin–Fluorouracil, or Chlorozotocin in the Treatment of Advanced Islet-Cell Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900073-9

7 January 2021

Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900073-9

7 January 2021

Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900073-9

7 January 2021

Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900073-9

7 January 2021

Prognostic factors in patients with endocrine tumours of the duodenopancreatic area

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900073-9

7 January 2021

Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900073-9

7 January 2021

Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900073-9

7 January 2021

Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900073-9

7 January 2021

High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900073-9

7 January 2021

Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900073-9

7 January 2021

[111In-DTPA-D-Phe1]octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900073-9

7 January 2021

Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900073-9

7 January 2021

Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900073-9

7 January 2021

10.1016/S0959-8049(01)00073-9

Identifiers

DOI

1 reference

25 November 2017

1 reference